Malaria vaccine 'could be less than two years away'

The introduction of a vaccine against malaria could be less than two years away following a trial by a British healthcare company.

GlaxoSmithKline has conducted successful trials of a vaccine against malaria. Credit: Reuters

The results of the trial by GlaxoSmithKline (GSK) demonstrated the most clinically advanced malaria vaccine candidate - RTS,S - continued to protect young children and infants from clinical malaria up to 18 months after vaccination.

Over a year and a half, the vaccine was shown to almost halve the number of malaria cases in children aged five to 17 months at first vaccination.

The study of more than 15,000 infants and young children found the vaccine reduced by around a quarter the malaria cases in infants aged six to 12 weeks at first vaccination.